|August 14, 2014|
|17:00 EDT||CVEO, PENN, CSC, BWC, CONN, SUNE, TIME, HTS, NOK, APC, AAPL, NOV, NRF, AER, AHL, RAD, CI, IACI, LRCX, CHMT||Greenlight Capital gives quarterly update on stakes |
NEW STAKES: Civeo (CVEO), AerCap (AER), Time Inc (TIME), Chemtura (CHMT), and Northstar Realty (NRF). INCREASED STAKES: Sunedison (SUNE), Lam Research (LRCX), National Oilwell Varco (NOV), Conn's (CONN), and IAC/InterActiveCorp (IACI). DECREASED STAKES: Apple (AAPL), Babcock & Wilcox (BWC), Cigna (CI), Anadarko (APC), and Computer Sciences Corp (CSC). LIQUIDATED STAKES: Rite Aid (RAD), Nokia (NOK), Penn National (PENN), Aspen Insurance (AHL), and Hatteras (HTS).
News For CVEO;AER;TIME;CHMT;NRF;SUNE;LRCX;NOV;CONN;IACI;AAPL;BWC;CI;APC;CSC;RAD;NOK;PENN;AHL;HTS From The Last 14 Days
|November 16, 2015|
|12:35 EDT||AAPL||Apple reaps 94% of global smartphone profits, Business Insider says|
Subscribe for More Information
|12:28 EDT||SUNE||On The Fly: Top stock stories at midday|
Stocks on Wall Street were mixed at midday as markets around the world, most notably in Europe, held up better than may have been expected after the terrorist attacks in Paris. ECONOMIC EVENTS: In the U.S., stock futures were pointing to a higher open early this morning, showing a good amount of resiliency in the face of the events in France this weekend. However, the futures weakened following the release of manufacturing data from the N.Y. region, leading to a slightly lower open for the broader market. The Empire State index edged up to -10.74 in November, which was improved from the -11.4 reading for last month but below expectations for a -6.50 reading. In Asia, Japan's gross domestic product declined 0.8% in the third quarter, missing expectations for a 0.2% decrease and taking the nation's economy back into recession. COMPANY NEWS: Starwood Hotels & Resorts (HOT) found a buyer, but it was not the one that recent reports had been foreshadowing. Starwood and Marriott (MAR) announced a merger agreement under which the companies will create the world's largest hotel company. Starwood, which had been linked in media reports to a number of other potential buyers in the past, including Hyatt (H) most recently, fell 6% following the deal announcement, while Marriott shares slid fractionally. MAJOR MOVERS: Among the notable gainers was JD.com (JD), which rallied 9.5% after the company reported third quarter earnings. Also higher was CONSOL Energy (CNX), which gained 6% after Business Insider reported that Greenlight Capital's David Einhorn reiterated the company as his "best idea" while presenting at the Robin Hood investors conference. Among the noteworthy losers was SunEdison (SUNE), which fell over 6.5% after quarterly filings showed that at least two prominent hedge funds have exited or trimmed their stakes in the company. Also lower was Clovis (CLVS), which was down 70% after it announced that the FDA requested additional data for rociletinib. INDEXES: Near midday, the Dow was up 68.18, or 0.4%, to 17,313.42, the Nasdaq was down 5.62, or 0.11%, to 4,922.27, and the S&P 500 was up 6.19, or 0.31%, to 2,029.23.
|11:30 EDT||SUNE||Loeb exits SunEdison while Deutsche says liquidity worries overdone|
Deutsche Bank said that investors' fears that SunEdison (SUNE) will run out of liquidity are unfounded, as the solar energy company is not poised to suffer any liquidity events. Meanwhile, quarterly filings are showing that several prominent hedge funds have exited or trimmed their stakes in SunEdison and another firm downgraded the shares of a SunEdison subsidiary. LIQUIDITY WORRIES OVERDONE: Investors are worried about SunEdison's liquidity, but these fears are overdone, wrote Deutsche Bank analyst Vishai Shah. Only about $3B of the company's total $12B debt consists of recourse loans, the analyst stated. Additionally, in the near-term, investors are primarily worried about a $510M payment that SunEdison has to make in connection with its acquisition of the company Wind Energy, according to the analyst. Although SunEdison will not be able to sell its wind projects to TerraForm (TERP) due to the "disarray" of alternative energy financing markets, SunEdison will instead drop the projects into one of its warehouses, enabling it to recognize cash margins for the projects, the analyst explained. Additionally, the interest owed by SunEdison's project development company will only amount to about $150M, versus the $210M per quarter shown on its income statement, Shah stated. The discrepancy is due to the consolidation of its subsidiaries and the non-recourse debt it holds, he explained. Shah kept a $28 price target and Buy rating on SunEdison shares. HEDGE FUND UPDATES: Leon Cooperman's Omega Advisors lowered its stake in SunEdison last quarter, while Dan Loeb's Third Point sold its entire stake in the solar energy company last quarter, their quarterly filings disclosing their positions as of September 30 revealed. TERRAFORM DOWNGRADE: There is "substantial doubt" about TeraForm's ability to profitably buy assets from SunEdison or third parties, according to UBS analyst Julien Dumoulin-Smith. The analyst said he reached this conclusion because of TeraForm's 10%+ dividend yield and deteriorating balance sheet. Given the yieldco's recently revealed need to invest significantly more capital in projects than expected, its balance sheet will be more stressed than he had predicted, the analyst explained. Dumoulin-Smith lowered his price target on TerraForm to $14 from $30 and downgraded the stock to Neutral from Buy. ANOTHER TO WATCH: After meeting with First Solar's (FSLR) management last week, Shah wrote today that he was more confident about the company's upcoming products and earnings. Although investors are concerned about the company's 2017 earnings outlook, its 2017 earnings should grow to over $4 per share that year, he believes. Among the factors that will increase First Solar's profits are cost reductions, capacity expansion, and strong backlog growth, he believes. Shah kept a Buy rating on the shares. PRICE ACTION: In late morning trading, SunEdison fell 8% to $4.53, TerraForm sank 9% to $12.56 after earlier reaching a 52-week low of $12.51 earlier in the session and First Solar was fractionally higher at $52.90.
|10:43 EDT||CSC||Options with increasing implied volatility|
Subscribe for More Information
|10:25 EDT||AAPL||UBS trims Apple target, says iPhone partner cut production forecast|
Hon Hai, which manufactures Apple's (AAPL) iPhones, expects to assemble significantly fewer iPhones this quarter than in the same period in 2014, UBS wrote in a note to investors today. WHAT'S NEW: Hon Hai Precision Industry, also known as Foxconn, is expected to assemble 10% fewer iPhones this quarter than in the same period in 2014, said UBS analyst Steven Milunovich, citing work from fellow UBS analyst Arthur Hsieh. Previously, companies that supply force touch components for iPhones saw a 10%-15% reduction in their orders, the analyst reported. These developments "are not encouraging," but Apple had previously ordered a large number of iPhones for Q4, according to Milunovich. Overall iPhone demand "could still be decent," he believes. However, the analyst lowered his iPhone sales estimate for Apple's March quarter to 61M from 62.5M, asserting that iPhone sales on China's November 11 Singles Day holiday may have come in below expectations. Based on October search volumes, he continues to believe that demand for iPhone units in the fourth quarter of the calendar year will be 75M, in-line with the consensus outlook. Milunovich trimmed his price target on Apple to $140 from $150 but kept a Buy rating on the shares. WHAT'S NOTABLE In a note to investors on November 10, Credit Suisse reported that it was cutting its estimates for 2016 iPhone sales. The firm expects sales of the device to fall 10.4% in the first quarter versus the same period in 2015, and it predicts that iPhone sales will decline 5.5% year-over-year in 2016. Suppliers with greater than 10% exposure to Apple include Avago (AVGO), SanDisk (SNDK), Analog Devices (ADI), Broadcom (BRCM), Texas Instruments (TXN), NXP Semiconductors (NXPI) and Fairchild (FCS), Credit Suisse reported. The firm said it continues to have a negative view of the smartphone sector. PRICE ACTION: In early trading, Apple added nearly 1% to $113.34.
|09:59 EDT||CI, SUNE||Omega bought Valeant in Q3, sold some SuneEdison|
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
|09:51 EDT||HTS||Hatteras Financial management to meet with JMP Securities|
Meetings to be held in the Mid-Atlantic area on November 16 and in New York on November 17 hosted by JMP Securities.
|09:37 EDT||SUNE, AAPL||Active equity options trading on open|
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
|09:06 EDT||RAD||Diplomat seen as compelling amid specialty pharmacy fallout|
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
|08:46 EDT||AAPL||4-inch iPhone 6c may be available in middle of 2016, Cult of Mac reports|
Subscribe for More Information
|08:44 EDT||AAPL||German watchdog launches probe into Apple, Amazon audio books pact, Reuters says|
Germany's Federal Cartel Office has initiated a probe into Apple's (AAPL) arrangement with Amazon (AMZN) for buying audiobooks, Reuters reports. The watchdog said that both companies had a long-term agreement for the purchase of audio books by Apple from Amazon via Apple's iTunes, the report says. Reference Link
|07:42 EDT||APC||Anadarko named a Top Pick at Cowen|
Cowen moved Anadarko (APC) to a Top Pick, citing valuation and the company's ability to execute large, complex mergers. Cowen noted Anadarko approached Apache (APA) and declined when the deal did not happen, but the firm sees material upside for Anadarko shares. Cowen reiterated its Outperform rating and $87 price target on Anadarko.
|07:17 EDT||NOV||Seaport Global to hold a conference|
Subscribe for More Information
|06:40 EDT||SUNE||Deutsche does not expect liquidity event for SunEdison|
Deutsche Bank analyst Vishal Shah says that based on analysis of recent regulatory filings and company guidance, he does not foresee any liquidity event for SunEdison (SUNE). The company could generate cash in 2016 post earn outs and debt payments, Shah tells investors in a research note. He reiterates a Buy rating on SunEdison following the recent weakness. The analyst has a $28 price target for shares. The developer and seller of photovoltaic energy solutions closed Friday up 39c to $4.93 but is down 35% over the past week. Shah this morning also reiterated a Buy rating on First Solar (FSLR) after meeting with management last week.
|06:37 EDT||AAPL||Apple's Cook: No plans to make 'converged' MacBook and iPad, Independent reports|
Apple has no plans to build a "converged" MacBook and iPad, the Independent reports, citing CEO Tim Cook. "We feel strongly that customers are not really looking for a converged Mac and iPad," Cook said. "Because what that would wind up doing, or what we're worried would happen, is that neither experience would be as good as the customer wants. So we want to make the best tablet in the world and the best Mac in the world. And putting those two together would not achieve either. You'd begin to compromise in different ways." Reference Link
|06:19 EDT||AAPL||Apple News fails to impress publishers, Digiday reports|
Subscribe for More Information
|06:05 EDT||AAPL||Apple price target lowered to $140 from $150 at UBS|
UBS analyst Steven Milunovich lowered his price target for Apple to $140 from $150 saying the stock's multiple is likely to be pressured until supply chain concerns are resolved. UBS analyst Arthur Hsieh indicates Hon Hai's Q4 iPhone assembly order forecast has been cut and should be down 10% year-over-year, Milunovich tells investors in a research note. The analyst is unclear what the order pullback means for iPhone shipments, but notes "it is not encouraging." Milunovich maintains his above-consensus December estimates for Apple, but trimmed his estimates for the March quarter. He keeps a Buy rating on Apple.
|06:02 EDT||CI||Anthem announces ISS recommends shareholders vote "For" Cigna acquisition|
Anthem (ANTM) announced that Institutional Shareholder Services has issued a report recommending that Anthem shareholders vote to approve the issuance of Anthem stock in the proposed acquisition of Cigna (CI) at the company's special meeting of shareholders to be held on Thursday, December 3, 2015. Anthem's board unanimously recommends that Anthem shareholders vote "FOR" the proposal to issue Anthem common stock to acquire Cigna, which is necessary to complete the transaction.
|05:56 EDT||SUNE||TerraForm Power downgraded to Neutral from Buy at UBS|
Subscribe for More Information
|November 15, 2015|
|19:49 EDT||AAPL||Apple CEO Cook expects 'huge' Watch sales this year, IE says|
In an interview with Irish Independent published Sunday, Apple CEO Tim Cook said he expects "huge" Apple Watch sales this year. Cook added that he sees iPad sales rebounding, and said the company does not plan a combined iPad-Mac device. Reference Link